Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

Overview of Hematopoiesis

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months….

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024

Same author

Monoclonal gammopathy of clinical signifi cance with osteosclerotic lesions - a case report and a literature review.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024

Same author

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.

American journal of hematology·2024

Same author

Treatment of adult patients with acute lymphoblastic leukemia in the Czech Republic in the period 2007-2020.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2023

Same author

First Search for Exclusive Diphoton Production at High Mass with Tagged Protons in Proton-Proton Collisions at sqrt[s]=13 TeV.

Physical review letters·2022

Same author

Odderon Exchange from Elastic Scattering Differences between pp and pp[over ¯] Data at 1.96 TeV and from pp Forward Scattering Measurements.

Physical review letters·2021

Search research articles

Related Experiment Videos

[Hematologic malignancies in pregnancy].

R Doubek¹, D Petrovová, J Kalvodová

¹Gynekologicko-porodnická klinika LF MU a FN, Brno. radandoubek@seznam.cz

Ceska Gynekologie

|June 12, 2009

Summary

Hematologic malignancies, such as Hodgkin's lymphoma and leukemia, rarely complicate pregnancy. Optimal management involves a multidisciplinary team and delivery after 36 weeks, preferably via vaginal birth.

Area of Science:

Hematology
Obstetrics
Oncology

Context:

Hematologic malignancies are rare in pregnancy, occurring in approximately 1 in 1,000 pregnancies.
Hodgkin's lymphoma is the most common, followed by leukemia, with myeloproliferative diseases being sporadic.
Nonspecific symptoms can delay diagnosis during pregnancy.

Purpose:

To review and summarize existing data on hematologic malignancies diagnosed during pregnancy.
To highlight diagnostic challenges and management strategies for these rare coexisting conditions.

Summary:

This review compiles data on hematologic cancers in pregnancy, emphasizing Hodgkin's lymphoma and leukemia.
Management requires a multidisciplinary team including hemato-oncologists and obstetricians.

Related Experiment Videos

Optimal delivery timing is post-36 weeks, with a preference for vaginal delivery over cesarean section.

Impact:

Informs clinical practice regarding the diagnosis and management of hematologic malignancies in pregnant patients.
Emphasizes the importance of a coordinated, multidisciplinary approach for improved maternal and fetal outcomes.
Provides guidance on delivery timing and method to optimize treatment and reduce risks.